SEEM anniversary meeting held in Belgrade

October 05, 2009

Arnhem, October 2009 -- On 9 and 10 October the anniversary South Eastern European Meeting (SEEM) will be held in the Yugoslav Drama Theatre (Jugoslovensko Dramsko Pozoriste) in Belgrade (RS). Professor Michael Marberger (Vienna, AT), chairman of the Regional Office of the European Association of Urology: "For the 5th time the SEEM will provide a platform where new experimental and clinical work from the region is presented to an international audience".

The Advisory Board selected a record number of 144 high-quality abstracts. Professor Sava Micic (Belgrade, RS), chairman of the meeting: "The challenging scientific programme is filled with a variety of subjects, such as - on Friday morning - bladder cancer, followed by the debate 'Urinary diversion at cystectomy: Continent is the way to go'".

In the afternoon, the focus is on Andrology with lectures about, among other things, the treatment of male infertility (S. Micic). Prof N Sofikitis, Ioannina (GR) tries to answer the question 'Who needs testosterone substitution and how?' Professor Chris Chapple (Sheffield, GB) is responsible for this year's State-of-the-Art lecture on 'Have we solved the problem of anterior urethral stricture disease?' Paediatric urology is extensively covered with several lectures on Saturday morning, as well as the panel debate 'Are we overdiagnosing prostate cancer?' chaired by Prof Chapple.

Poster viewing sessions provide excellent chances for younger urologists to profile themselves and display their abstracts. This year the topics are Bladder cancer and urinary diversion, BPH and prostate biopsy, incontinence and overactive bladder, Testicular cancer, infertility, erectile dysfunction, Kidney cancer, Prostate cancer and, on Saturday morning, Stone disease, Trauma and reconstruction and Miscellaneous.
For more information about the meeting, please go to or send an email to

European Association of Urology

Related Prostate Cancer Articles from Brightsurf:

Low risk of cancer spread on active surveillance for early prostate cancer
Men undergoing active surveillance for prostate cancer have very low rates - one percent or less - of cancer spread (metastases) or death from prostate cancer, according to a recent study published in the Journal of Urology®, an Official Journal of the American Urological Association (AUA).

ESMO 2020: Breast cancer drug set to transform prostate cancer treatment
A drug used to treat breast and ovarian cancer can extend the lives of some men with prostate cancer and should become a new standard treatment for the disease, concludes a major trial which is set to change clinical practice.

Major trial shows breast cancer drug can hit prostate cancer Achilles heel
A drug already licensed for the treatment of breast and ovarian cancers is more effective than targeted hormone therapy at keeping cancer in check in some men with advanced prostate cancer, a major clinical trial reports.

The Lancet: Prostate cancer study finds molecular imaging could transform management of patients with aggressive cancer
Results from a randomised controlled trial involving 300 prostate cancer patients find that a molecular imaging technique is more accurate than conventional medical imaging and recommends the scans be introduced into routine clinical practice.

Common genetic defect in prostate cancer inspires path to new anti-cancer drugs
Researchers found that, in prostate cancer, a mutation leading to the loss of one allele of a tumor suppressor gene known as PPP2R2A is enough to worsen a tumor caused by other mutations.

First prostate cancer therapy to target genes delays cancer progression
For the first time, prostate cancer has been treated based on the genetic makeup of the cancer, resulting in delayed disease progression, delayed time to pain progression, and potentially extending lives in patients with advanced, metastatic prostate cancer, reports a large phase 3 trial.

Men taking medications for enlarged prostate face delays in prostate cancer diagnosis
University of California San Diego School of Medicine researchers report that men treated with medications for benign prostatic hyperplasia (enlarged prostate) experienced a two-year delay in diagnosis of their prostate cancer and were twice as likely to have advanced disease upon diagnosis.

CNIO researchers confirm links between aggressive prostate cancer and hereditary breast cancer
The study has potential implications for families with members suffering from these types of tumours who are at an increased risk of developing cancer.

Distinguishing fatal prostate cancer from 'manageable' cancer now possible
Scientists at the University of York have found a way of distinguishing between fatal prostate cancer and manageable cancer, which could reduce unnecessary surgeries and radiotherapy.

Researchers find prostate cancer drug byproduct can fuel cancer cells
A genetic anomaly in certain men with prostate cancer may impact their response to common drugs used to treat the disease, according to new research at Cleveland Clinic.

Read More: Prostate Cancer News and Prostate Cancer Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to